Evan David Seigerman
Stock Analyst at BMO Capital
(3.57)
# 862
Out of 5,055 analysts
51
Total ratings
53.33%
Success rate
6.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $8.77 | +25.43% | 5 | Nov 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $55 | $48.46 | +13.50% | 7 | Oct 14, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $234.00 | +2.56% | 8 | Sep 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $600 → $640 | $704.31 | -9.13% | 8 | Aug 4, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $22.46 | +15.76% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $95.88 | +14.73% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $24.01 | +16.62% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $11.04 | -9.42% | 1 | May 5, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $92.86 | +3.38% | 4 | Feb 5, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $341.71 | +1.26% | 4 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $112 | $89.65 | +24.93% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $37.44 | +167.09% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.08 | +43.54% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $4.75 | -36.84% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,021.70 | -61.24% | 1 | Sep 6, 2022 |
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $8.77
Upside: +25.43%
Novo Nordisk
Oct 14, 2025
Maintains: Market Perform
Price Target: $50 → $55
Current: $48.46
Upside: +13.50%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $234.00
Upside: +2.56%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Outperform
Price Target: $600 → $640
Current: $704.31
Upside: -9.13%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $22.46
Upside: +15.76%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $95.88
Upside: +14.73%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $24.01
Upside: +16.62%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $11.04
Upside: -9.42%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $92.86
Upside: +3.38%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $341.71
Upside: +1.26%
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $89.65
Upside: +24.93%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $37.44
Upside: +167.09%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.08
Upside: +43.54%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $4.75
Upside: -36.84%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,021.70
Upside: -61.24%